6 Matching Annotations
  1. May 2021
    1. Larger, blinded, randomized control trials are still ongoing to confirm the efficacy of CP treatment, the RECOVERY trial in Oxford is one such Phase 3 trial of CP (NCT04381936).

      The RECOVERY trial in Oxford, with 5795 patients who were randomly allocated to receive convalescent plasma treatment and 5763 who received usual care alone, found that there was no statistically significant difference for 28-day mortality (24% for both groups, p-0.93) or the proportion of patients discharged from hospital within 28 days (66% CP vs 67% control, p=0.50) for the two groups. Additonally for patients without mechanical ventilation, there was no stastically significant difference in the intubation rate (28% CP vs 29% control, p=0.79).

      https://doi.org/10.1101/2021.03.09.21252736

      The trial showed convalescent plasma therapy had no benefit to patients with COVID-19. As a result the UK's health service has stopped collecting convalescent plasma from patients who had recovered from COVID-19.

      https://www.bbc.co.uk/news/health-55681051

      Additonally the NIH have halted a convalescent plasma trial for COVID-19 patients with mild symptoms stating that the "study shows that the treatment is safe, but provides no signifcant benefit in this group".

      https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms

  2. Dec 2020
    1. Emily. J. Miller. - FDA {@FDASpox} (2020) Convalescent plasma has shown to be beneficial for 35% of patients. This risk reduction figure - shown in chart below - is from @MayoClinic data from expanded access program that was analyzed by FDAA for the emergency use authorization announced today. Twitter. Retrieved from: https://twitter.com/FDASpox/status/1297706985039835136

  3. Sep 2020
  4. Aug 2020
  5. Jul 2020
  6. Jun 2020
    1. Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619